Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

AIDS

Volumn 24, Issue 16, 2010, Pages 2451-2460

  Yukl, Steven A ^a   Shergill, Amandeep K ^a   McQuaid, Kenneth ^a   Gianella, Sara ^b   Lampiris, Harry ^a   Hare, C Bradley ^a   Pandori, Mark ^c   Sinclair, Elizabeth ^a   Günthard, Huldrych F ^b   Fischer, Marek ^b   Wong, Joseph K ^a   Havlir, Diane V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Department of Public Health ^*  (United States)

Author keywords

ART; Gut; HIV; Intensification; Intestine; Raltegravir; T cell

Indexed keywords

DARUNAVIR; EFAVIRENZ; RALTEGRAVIR; VIRUS DNA; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COLON; DRUG BLOOD LEVEL; DRUG EFFECT; DUODENUM; GASTROINTESTINAL ENDOSCOPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; ILEUM; INTESTINE BIOPSY; INTESTINE CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PYRROLIDINONES; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; YOUNG ADULT;

EID: 78549245806     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ef7bb     Document Type: Article

References (44)

1. DinosoJB, Kim SY, Wiegand AM, Palmer SE, GangeSJ, Cranmer L, etal. Treatment intensification does not reduce residual HIV- 1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009;106:9403-9408.
2. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189:1452-1465.
3. Persaud D, Siberry GK, Ahonkhai A, Kajdas J, Monie D, Hutton N, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004;78:968-979.
4. Joos B, Fischer M, Kuster H, Pillai SK, WongJK, Boni J, etal. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA 2008; 105:16725-16730.
5. Wiegand A, Cossarini F, Poethke C, Kearney M, Spindler J, O'shea A, et al. Raltegravir intensification does not reduce persistent HIV-1 viremia in treatment-experienced patients. 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010);2010.
6. Joly V, Fagard C, Descamps D, Colin de Verdiere N, Raffi F, Tabuteau S, et al. Intensification of HAART through the addition of enfuvirtide in naive HIV-infected patients with severe immunosuppression does not improve immunologic response: results of a prospective randomized multicenter trial (ApOL- LO-ANRS 130). 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010); 2010.
7. EveringT, Mehandru S, Poles M, Racz P, Tenner-Racz K, Mohri H, et al. Antiviral and immunologic effects of intensification of suppressive ART with maraviroc, a CCR5 antagonist. 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010); 2010.
8. Hatano H, Hayes T, Dahl V, Sinclair E, Lee T-H, Hunt P, et al. Raltegravir intensification in antiretroviral-treated patients exhibiting a suboptimal CD4+ T cell response. 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010); 2010.
9. McMahon D, Jones J, Wiegand A, GangeSJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010;50:912-919.
10. Sharkey ME, Teo I, Greenough T, Sharova N, Lazuriaga K, Sullivan J, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nature Med 2000;6:76-81.
11. Petitjean G, Al Tabaa Y, Tuaillon E, Mettling C, Baillat V, Reynes J, et al. Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology 2007; 4:60.
12. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005;115:3250-3255.
13. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187:1534-1543.
14. Ramratnam B, Ribeiro R, He T, Chung C, Simon V, Vanderhoeven J, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004; 35:33-37.
15. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, Wong JK. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antire-troviral therapy for five years. J Virol 2003;77:11212-11219.
16. Kolber MA, Saenz MO, Tanner TJ, Arheart KL, Pahwa S, Liu H. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation. Clin Immunol 2008;126:315-321.
17. Gutierrez C, Diaz L, Hernandez-Novoa B, Vallejo A, Page C, Lorente R, et al. Effect of the intensification with a CCR5 antagonist on the decay of the latent reservoir and residual viremia. 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010); 2010.
18. Wilkin T, Lalama C, Tenorio A, Landay A, Ribaudo H, McKinnon J, et al. Maraviroc intensification for suboptimal CD4+ cell response despite sustained virologic suppression: ACTG 5256. 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010); 2010.
19. Buzon M, Massanella M, Llibre J, Esteve A, Puertas M, Palmer S, et al. HIV-1 replication and immune dynamics are impacted by raltegravir intensification of HAART-suppressed patients. 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010);2010.
20. Critchfield JW, Lemongello D, Walker DH, Garcia JC, Asmuth DM, Pollard RB, Shacklett BL. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol 2007;81:5460-5471.
21. Shacklett BL, Critchfield JW, Lemongello D. Isolating mucosal lymphocytes from biopsy tissue for cellular immunology assays. Methods Mol Biol 2009; 485:347-356.
22. Anton PA, Poles MA, Elliott J, Mao SH, McGowan I, Lenz HJ, Chen IS. Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsies. J Virol Methods 2001;95:65-79.
23. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Mi- chau C, Kerdraon R, et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term nonprogressors. AIDS 2008; 22:1880-1882.
24. Hunt PW, Brenchley J, Sinclair E, McCuneJM, Roland M, Page- Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with un- detectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126-133.
25. Swanson P, Huang S, Abravaya K, de Mendoza C, Soriano V, Devare SG, Hackett J Jr. Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods 2007;141:49-57.
26. Tang N, Huang S, Salituro J, Mak WB, Cloherty G, Johanson J, et al. A RealTime HIV-1 viral load assay for automated quanti- tation of HIV-1 RNA in genetically diverse group M subtypes AH, group O and group N samples. J Virol Methods 2007; 146:236-245.
27. Fischer M, Joos B, Niederost B, Kaiser P, Hafner R, von Wyl V, et al. Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 2008;5:107.
28. Kaiser P, Joos B, Niederost B, Weber R, Gunthard HF, Fischer M. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. JVirol2007; 81:9693-9706.
29. Althaus CF, Gianella S, Rieder P, von Wyl V, Kouyos RD, Niederost B, et al. Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. J Virol Methods 2010;165:151-160.
30. Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Gunthard HF. Cellular viral rebound after cessation of potent antiretro- viral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. J Infect Dis 2004;190:1979-1988.
31. Fischer M, HuberW, Kallivroussis A, Ott P, Opravil M, Luthy R, et al. Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues. J Clin Microbiol 1999;37:1260-1264.
32. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008;197:714-720.
33. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008;197:411-419.
34. Phillips DM. The role of cell-to-cell transmission in HIV infection. AIDS 1994;8:719-731.
35. Grossman Z, Feinberg M, Kuznetsov V, Dimitrov D, Paul W. HIV infection: how effective is drug combination treatment? Immunol Today 1998;19:528-532.
36. Piguet V, Sattentau Q. Dangerous liaisons at the virological synapse. J Clin Invest 2004;114:605-610.
37. Jolly C, Sattentau QJ. Retroviral spread by induction of virological synapses. Traffic 2004;5:643-650.
38. Haller C, Fackler OT. HIV-1 at the immunological and T- lymphocytic virological synapse. Biol Chem 2008; 389:1253-1260.
39. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 2008;6:815-826.
40. Martin N, Sattentau Q. Cell-to-cell HIV-1 spread and its implications for immune evasion. Curr Opin HIV AIDS 2009; 4:143-149.
41. Rudnicka D, Feldmann J, Porrot F, Wietgrefe S, Guadagnini S, Prevost MC, et al. Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. J Virol 2009;83:6234-6246.
42. Puigdomenech I, Massanella M, Cabrera C, Clotet B, Blanco J. On the steps of cell-to-cell HIV transmission between CD4 T cells. Retrovirology 2009; 6:89.
43. Sol-Foulon N, Moris A, Nobile C, Boccaccio C, Engering A, Abastado JP, et al. HIV-1 Nef-induced upregulation of DC- SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 2002;16:145-155.
44. Grossman Z, Polis M, Feinberg MB, Grossman Z, Levi I, Jankelevich S, etal. Ongoing HIVdissemination during HAART. Nat Med 1999;5:1099-1104.